TrialBMC pharmacology & toxicology2025
Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis.
Min Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.